Stocks / ALNY vs DXCM

Alnylam Pharmaceuticals, Inc. (ALNY) vs DexCom, Inc. (DXCM)

Alnylam Pharmaceuticals, Inc. and DexCom, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.

ALNY is the larger company ($38.9B vs $34.8B). On the fundamentals, ALNY grows revenue faster (49.8% vs 19.3%); DXCM earns a higher net margin (17.9% vs 8.4%); ALNY has the stronger return on equity (39.8% vs 30.5%). Over the last five years, ALNY returned 71.9% vs -31.4%. On the filings, DXCM carries fewer potential red flags (0 vs 2). Full numbers below — the stronger figure on each row is in green.

AI verdict — ALNY vs DXCM, read from the filings

The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.

 Alnylam Pharmaceuticals, Inc. (ALNY)DexCom, Inc. (DXCM)
Market cap$38.9B$34.8B
Revenue (latest FY)$3.71B$4.66B
Net income (latest FY)$313.75M$836.30M
Revenue growth (5y CAGR)49.8%19.3%
Net margin8.4%17.9%
Return on equity39.8%30.5%
P/E ratio73.037.4
Dividend yield
Profitable years (of last 10)17
Positive free cash flowYesYes

Performance — ALNY vs DXCM

Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.

 Alnylam Pharmaceuticals, Inc. (ALNY)DexCom, Inc. (DXCM)
1-year return-10.6%20.5%
3-year return53.4%-10.1%
5-year return71.9%-31.4%
10-year return425.1%298.8%
52-week range$283.10–$495.55$54.11–$92.59

Verify the comparison

Use the filing period and source shown by each tool before treating two figures as comparable.

Compare with another company:

See the full ALNY vs DXCM breakdown

Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.

Open ALNY's full financials →   Open DXCM's full financials →

More comparisons

Frequently asked questions

Which is bigger, ALNY or DXCM?

Alnylam Pharmaceuticals, Inc. is larger by market capitalization — $38.9B versus $34.8B.

Which grows faster, ALNY or DXCM?

Over the last five fiscal years, Alnylam Pharmaceuticals, Inc. grew revenue faster — 49.8%/yr versus 19.3%/yr, computed from SEC-filed statements.

Where does this data come from?

All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.

Keep exploring

ALNY fundamentals → · DXCM fundamentals → · All 1,500+ companies → · Free screener →